International Journal of Clinical Research

Objective: To investigate the clinical efficacy of moxifloxacin in the treatment of community-acquired pneumonia. Method: A total of 58 patients with community-acquired pneumonia admitted to our hospital from February 2023 to February 2024 were selected and allocated into a control group (29 cases) and a guidance group (29 cases) according to the distribution of all patients. Finally, statistical analysis was conducted on the treatment effectiveness and adverse complications of the patients. Result: After analysis, the incidence of complications in the guidance group (20.83%) was significantly lower than that in the control group (54.16%), indicating a comparative significance (P<0.05). The treatment effect of the guidance group patients has significantly improved, and the data comparison shows significant statistical differences (P<0.05). Conclusion: Moxifloxacin has multiple advantages in the treatment of community-acquired pneumonia, including ease of use, no need for skin testing, one-time administration, and relatively high safety. Therefore, authoritative treatment guidelines both domestically and internationally strongly recommend the use of moxifloxacin as the preferred medication for the treatment of all community-acquired pneumonia.

Moxifloxacin; Community acquired pneumonia; Clinical efficacy; observation